Abstract
Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate-2/high International Prognostic Score System risk, safety and efficacy data in intermediate-1 patients are limited. We report on 70 intermediate-1 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG-MRT criteria. At 6 months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3 months, ruxolitinib-induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event ≥grade 2. Most (82.6%) patients were still on therapy after a median follow-up of 27 months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and pot...Continue Reading
References
Jan 1, 1987·Journal of Chronic Diseases·M E CharlsonC R MacKenzie
Oct 15, 1998·The American Journal of Clinical Nutrition
Aug 31, 2007·Leukemia·G BarosiUNKNOWN International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)
Nov 8, 2008·Blood·Francisco CervantesAyalew Tefferi
Apr 10, 2009·Blood·James W VardimanClara D Bloomfield
Oct 16, 2010·Blood·Francesco PassamontiAyalew Tefferi
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Jun 2, 2012·British Journal of Haematology·John T ReillyUNKNOWN Writing group: British Committee for Standards in Haematology
Jun 22, 2012·Blood·Srdan VerstovsekFrancesco Passamonti
Jan 8, 2013·Cancer Letters·Massimo BrecciaGiuliana Alimena
Jul 11, 2013·Blood·Ayalew TefferiGiovanni Barosi
Nov 1, 2013·Blood·Francisco CervantesUNKNOWN COMFORT-II investigators
Nov 30, 2013·Blood·Annkristin HeineDominik Wolf
Apr 1, 2015·British Journal of Haematology·Adam J MeadClaire Harrison
Jun 13, 2015·Haematologica·Alessandro M VannucchiUNKNOWN COMFORT Investigators
Jun 2, 2016·Haematologica·Haifa Kathrin Al-AliAlessandro M Vannucchi
Oct 5, 2016·American Journal of Hematology·Nicola PolverelliFrancesca Palandri
Oct 16, 2016·Leukemia·M MarchettiT Barbui
Nov 28, 2016·Annals of Hematology·Massimo BrecciaRoberto Latagliata
Mar 1, 2014·Therapeutic Innovation & Regulatory Science·David K RaynorDavid Bryant
Citations
Aug 31, 2019·British Journal of Haematology·Emanuela Sant'AntonioElisa Rumi
Apr 17, 2020·Leukemia & Lymphoma·Prithviraj Bose, Srdan Verstovsek
Feb 26, 2020·Leukemia & Lymphoma·Giulia BenevoloMargherita Maffioli
Dec 28, 2019·Haematologica·Anders Lindholm SørensenHans Carl Hasselbalch
Oct 22, 2018·Annals of Hematology·Francesca PalandriMargherita Maffioli
Sep 27, 2019·Current Fungal Infection Reports·Marissa A ZarakasMichail S Lionakis
Dec 14, 2019·Annals of Hematology·Massimo BrecciaFrancesca Palandri
Sep 10, 2020·HemaSphere·Prithviraj Bose, Srdan Verstovsek
Feb 10, 2018·Current Medicinal Chemistry·Felice RivelleseFrancesca Wanda Rossi
Dec 18, 2020·Expert Opinion on Drug Safety·Giacomo Coltro, Alessandro M Vannucchi
Oct 16, 2020·Haematologica·Anders Lindholm SørensenHans Carl Hasselbalch
Jul 6, 2021·Hematological Oncology·Francesco PassamontiAlessandro M Vannucchi
Dec 18, 2021·Blood Research·Fatma ArikanTulin Tuglular